A novel molecular diagnostic of glioblastomas: Detection of an extracellular fragment of protein tyrosine phosphatase μ

Neoplasia

Volumn 12, Issue 4, 2010, Pages 305-316

  Burden Gulley, Susan M ^a   Gates, Theresa J ^a   Burgoyne, Adam M ^a   Cutter, Jennifer L ^b   Lodowski, David T ^a   Robinson, Shenandoah ^a   Sloan, Andrew E ^a   Miller, Robert H ^a   Basilion, James P ^b   Brady Kalnay, Susann M ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Case Western Reserve University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE MU; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; ENZYME BINDING; FEMALE; FLUORESCENCE ANALYSIS; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MOLECULAR PROBE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN EXPRESSION; TUMOR DIAGNOSIS; TUMOR LOCALIZATION; TUMOR XENOGRAFT;

EID: 77951687837     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.91940     Document Type: Article

References (45)

1. Ichimura K, Ohgaki H, Kleihues P, and Collins VP (2004). Molecular pathogenesis of astrocytic tumours. J Neurooncol 70, 137-160.
2. Louis DN, Ohgaki H, Wiestler OD, and Cavenee WK (2007). World Health Organization Classification of Tumours of the Nervous System. IARC, Lyon, France.
3. Louis DN (2006). Molecular pathology of malignant gliomas. Annu Rev Pathol 1, 97-117.
4. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, et al. (2007). Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21, 2683-2710.
5. Sanai N and Berger MS (2008). Glioma extent of resection and its impact on patient outcome. Neurosurgery 62, 753-764; discussion 264-756.
6. Nakada M, Nakada S, Demuth T, Tran NL, Hoelzinger DB, and Berens ME (2007). Molecular targets of glioma invasion. Cell Mol Life Sci 64, 458-478.
7. Sorensen AG, Batchelor TT, Wen PY, Zhang WT, and Jain RK (2008). Response criteria for glioma. Nat Clin Pract Oncol 5, 634-644.
8. Brady-Kalnay SM (2001). Protein tyrosine phosphatases. In Cell Adhesion: Frontiers in MolecularBiology. Vol 39. M Beckerle(Ed).Oxford University Press, Oxford,UK. pp. 217-258.
9. Ensslen-Craig SE and Brady-Kalnay SM (2004). Receptor protein tyrosine phosphatases regulate neural development and axon guidance. Dev Biol 275, 12-22.
10. Tonks NK (2006). Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 7, 833-846.
11. Burden-Gulley SM and Brady-Kalnay SM (1999). PTPμ regulates N-cadherin- dependent neurite outgrowth. J Cell Biol 144, 1323-1336.
12. Burgoyne AM, Palomo JM, Phillips-Mason PJ, Burden-Gulley SM, Major DL, Zaremba A, Robinson S, Sloan AE, Vogelbaum MA, Miller RH, et al. (2009). PTPμ suppresses glioblastoma cell migration and dispersal. J Neurooncol 11, 767-778.
13. Brady-Kalnay SM, Flint AJ, and Tonks NK (1993). Homophilic binding of PTPμ, a receptor-type protein tyrosine phosphatase, can mediate cell-cell aggregation. J Cell Biol 122, 961-972.
14. Gebbink MFBG, Zondag GCM, Wubbolts RW, Beijersbergen RL, van Etten I, and Moolenaar WH (1993). Cell-cell adhesion mediated by a receptor-like protein tyrosine phosphatase. J Biol Chem 268, 16101-16104.
15. Zondag G, Koningstein G, Jiang YP, Sap J, Moolenaar WH, and Gebbink M (1995). Homophilic interactions mediated by receptor tyrosine phosphatases μ and κ. J Biol Chem 270, 14247-14250.
16. Brady-Kalnay SM and Tonks NK (1994). Identification of the homophilic binding site of the receptor protein tyrosine phosphatase PTPμ. J Biol Chem 269, 28472-28477.
17. Del Vecchio RL and Tonks NK (2005). The conserved immunoglobulin domain controls the subcellular localization of the homophilic adhesion receptor protein- tyrosine phosphatase μ. J Biol Chem 280, 1603-1612.
18. Cismasiu VB, Denes SA, Reilander H, Michel H, and Szedlacsek SE (2004). The MAM (meprin/A5-protein/PTPμ) domain is a homophilic binding site promoting the lateral dimerization of receptor-like protein-tyrosine phosphatase μ. J Biol Chem 279, 26922-26931.
19. Aricescu AR, Hon WC, Siebold C, Lu W, van der Merwe PA, and Jones EY (2006). Molecular analysis of receptor protein tyrosine phosphatase μ-mediated cell adhesion. EMBO J 25, 701-712.
20. Aricescu AR, Siebold C, Choudhuri K, Chang VT, Lu W, Davis SJ, van der Merwe PA, and Jones EY (2007). Structure of a tyrosine phosphatase adhesive interaction reveals a spacer-clamp mechanism. Science 317, 1217-1220.
21. Burgoyne AM, Phillips-Mason PJ, Burden-Gulley SM, Robinson S, Sloan AE, Miller RH, and Brady-Kalnay SM (2009). Proteolytic cleavage of PTPμ regulates glioblastoma cell migration. Cancer Res 69, 6960-6968.
22. Tyminski E, Leroy S, Terada K, Finkelstein DM, Hyatt JL, Danks MK, Potter PM, Saeki Y, and Chiocca EA (2005). Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan. Cancer Res 65, 6850-6857.
23. Tyagi M and Karn J (2007). CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J 26, 4985-4995.
24. Campman M, Yoshizumi M, Seidah NG, Lee ME, Bianchi C, and Haber E (1996). Increased proteolytic processing of protein tyrosine phosphatase μ in confluent vascular endothelial cells: the role of PC5, a member of the subtilisin family. Bio-chemistry 35, 3797-3802.
25. Bianchi C, Sellke FW, and Neel BG (1999). Receptor-type protein-tyrosine phosphatase μ is expressed in specific vascular endothelial beds in vivo. Exp Cell Res 248, 329.
26. Koop EA, Lopes SM, Feiken E, Bluyssen HA, van der Valk M, Voest EE, Mummery CL, Moolenaar WH, and Gebbink MF (2003). Receptor protein tyrosine phosphatase μ expression as a marker for endothelial cell heterogeneity; analysis of RPTPμ gene expression using LacZ knock-in mice. Int J Dev Biol 47,345-354.
27. Koop EA, Gebbink MF, Sweeney TE, Mathy MJ, Heijnen HF, Spaan JA, Voest EE, Van Bavel E, and Peters SL (2005). Impaired flow-induced dilation in mesenteric resistance arteries from receptor protein tyrosine phosphatase-μ-deficient mice. Am J Physiol Heart Circ Physiol 288, H1218-H1223.
28. Sui XF, Kiser TD, Hyun SW, Angelini DJ, Del Vecchio RL, Young BA, Hasday JD, Romer LH, Passaniti A, Tonks NK, et al. (2005). Receptor protein tyrosine phosphatase μ regulates the paracellular pathway in human lung microvascular endothelia. Am J Pathol 166, 1247-1258.
29. Tysnes BB and Mahesparan R (2001). Biological mechanisms of glioma invasion and potential therapeutic targets. J Neurooncol 53, 129-147.
30. Demuth T and Berens ME (2004). Molecular mechanisms of glioma cell migration and invasion. J Neurooncol 70, 217-228.
31. Rao JS (2003). Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 3, 489-501.
32. Sathornsumetee S and Rich JN (2008). Designer therapies for glioblastoma multiforme. Ann N Y Acad Sci 1142, 108-132.
33. Ensslen-Craig SE and Brady-Kalnay SM (2005). PTP μ expression and catalytic activity are required for PTP μ-mediated neurite outgrowth and repulsion. Mol Cell Neurosci 28, 177-188.
34. Aricescu AR, Siebold C, and Jones EY (2008). Receptor protein tyrosine phosphatase μ: measuring where to stick. Biochem Soc Trans 36, 167-172.
35. Anders L, Mertins P, Lammich S, Murgia M, Hartmann D, Saftig P, Haass C, and Ullrich A (2006).Furin-,ADAM10-,andgamma-secretase-mediatedcleavage of a receptor tyrosine phosphatase and regulation of β-catenin's transcriptional activity. Mol Cell Biol 26, 3917-3934.
36. Roy R, Yang J, and Moses MA (2009). Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 27, 5287-5297.
37. Pruessmeyer J and Ludwig A (2009). The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer. Semin Cell Dev Biol 20, 164-174.
38. Streuli M, Krueger N, Ariniello P, Tang M, Munro J, Blattler W, Adler D, Disteche C, and Saito H (1992). Expression of the receptor-linked protein tyrosine phosphatase LAR: proteolytic cleavage and shedding of the CAM-like extracellular region. EMBO J 11, 897-907.
39. Haapasalo A, Kim DY, Carey BW, Turunen MK, Pettingell WH, and Kovacs DM (2007). Presenilin/gamma-secretase-mediated cleavage regulates association of leukocyte-common antigen-related (LAR) receptor tyrosine phosphatase with β-catenin. J Biol Chem 282, 9063-9072.
40. Chow JP, Fujikawa A, Shimizu H, and Noda M (2008). Plasmin-mediated processing of protein tyrosine phosphatase receptor type ζ in the mouse brain. Neurosci Lett 442,208-212.
41. Barr AJ, Ugochukwu E, Lee WH, King ON, Filippakopoulos P, Alfano I, Savitsky P, Burgess-Brown NA, Muller S, and Knapp S (2009). Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell 136, 352-363.
42. Mariani L, Beaudry C, McDonough WS, Hoelzinger DB, Kaczmarek E, Ponce F, Coons SW, Giese A, Seiler RW, and Berens ME (2001). Death-associated protein 3 (Dap-3) is overexpressed in invasive glioblastoma cells in vivo and in glioma cell lines with induced motility phenotype in vitro. Clin Cancer Res 7, 2480-2489.
43. Hoelzinger DB, Mariani L, Weis J, Woyke T, Berens TJ, McDonough WS, Sloan A, Coons SW, and Berens ME (2005).Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia 7, 7-16.
44. Stummer W, Novotny A, Stepp H, Goetz C, Bise K, and Reulen HJ (2000). Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 93, 1003-1013.
45. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, et al. (2001). A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95, 190-198.